AU2019321186B2 - Immunogenic compositions and uses thereof - Google Patents

Immunogenic compositions and uses thereof Download PDF

Info

Publication number
AU2019321186B2
AU2019321186B2 AU2019321186A AU2019321186A AU2019321186B2 AU 2019321186 B2 AU2019321186 B2 AU 2019321186B2 AU 2019321186 A AU2019321186 A AU 2019321186A AU 2019321186 A AU2019321186 A AU 2019321186A AU 2019321186 B2 AU2019321186 B2 AU 2019321186B2
Authority
AU
Australia
Prior art keywords
antigen
self
replicating rna
sam
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019321186A
Other languages
English (en)
Other versions
AU2019321186A1 (en
Inventor
Sylvie BERTHOLET GIRARDIN
Arun Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2019321186A1 publication Critical patent/AU2019321186A1/en
Application granted granted Critical
Publication of AU2019321186B2 publication Critical patent/AU2019321186B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2019321186A 2018-08-17 2019-08-16 Immunogenic compositions and uses thereof Active AU2019321186B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719219P 2018-08-17 2018-08-17
US62/719,219 2018-08-17
PCT/EP2019/072052 WO2020035609A2 (en) 2018-08-17 2019-08-16 Immunogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2019321186A1 AU2019321186A1 (en) 2021-02-18
AU2019321186B2 true AU2019321186B2 (en) 2024-05-23

Family

ID=67766133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019321186A Active AU2019321186B2 (en) 2018-08-17 2019-08-16 Immunogenic compositions and uses thereof

Country Status (7)

Country Link
US (2) US12083174B2 (enExample)
EP (1) EP3836963A2 (enExample)
JP (1) JP2021534182A (enExample)
CN (1) CN113164584A (enExample)
AU (1) AU2019321186B2 (enExample)
CA (1) CA3109165A1 (enExample)
WO (1) WO2020035609A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12290556B2 (en) 2017-12-18 2025-05-06 Intervet Inc. Swine influenza a virus vaccine
CA3171231A1 (en) 2020-03-09 2021-09-16 Sean Michael Sullivan Compositions and methods for inducing immune responses
CA3173793A1 (en) * 2020-04-03 2021-10-07 Andrew Ferguson Infectious disease antigens and vaccines
EP4153223A1 (en) * 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
US20230277649A1 (en) * 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
JP2023551982A (ja) * 2020-12-02 2023-12-13 セキラス インコーポレイテッド マルチシストロン性ｒｎａワクチン及びその使用
JPWO2022244825A1 (enExample) * 2021-05-19 2022-11-24
US20250019745A1 (en) * 2021-11-29 2025-01-16 Replicate Bioscience, Inc. Methods of generating self-replicating rna molecules
WO2023213378A1 (en) * 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
US20240009296A1 (en) * 2022-07-10 2024-01-11 Pfizer Inc. Self-amplifying rna encoding an influenza virus antigen
KR20250140103A (ko) * 2023-02-09 2025-09-24 화이자 인코포레이티드 핵산 및 이의 용도
WO2024254461A2 (en) * 2023-06-07 2024-12-12 Nutech Ventures Methods and compositions for vaccine development and delivery
WO2024261648A1 (en) * 2023-06-19 2024-12-26 Seqirus Inc. Multivalent subtype influenza vaccine
CN117205309B (zh) * 2023-11-07 2024-02-02 今发制药(南京)有限公司 一种流感免疫原组合物和制备方法及其用途
WO2025210141A1 (en) * 2024-04-05 2025-10-09 Boehringer Ingelheim Vetmedica Gmbh Delivery system useful for topical administration of rna

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3449910A1 (en) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
BR112013004879A2 (pt) 2010-08-31 2018-04-24 Novartis Ag lipossomas pequenos para entrega de rna que codifica imunogénio
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
AU2012280901B2 (en) * 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP4014966A1 (en) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
RU2649133C2 (ru) * 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US20140271829A1 (en) * 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
US10022436B2 (en) * 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNETTE B. VOGEL ET AL: "Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses", MOLECULAR THERAPY, vol. 26, no. 2, 1 February 2018 (2018-02-01), pages 446 - 455. *
FRANCESCO SCORZA ET AL: "New Kids on the Block: RNA-Based Influenza Virus Vaccines", VACCINES, vol. 6, no. 2, 1 April 2018 (2018-04-01), pages 20, XP055643919, DOI: 10.3390/vaccines6020020 *

Also Published As

Publication number Publication date
EP3836963A2 (en) 2021-06-23
US12083174B2 (en) 2024-09-10
US20210252133A1 (en) 2021-08-19
WO2020035609A2 (en) 2020-02-20
CA3109165A1 (en) 2020-02-20
WO2020035609A3 (en) 2020-05-28
AU2019321186A1 (en) 2021-02-18
US20250064916A1 (en) 2025-02-27
CN113164584A (zh) 2021-07-23
JP2021534182A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
US20250064916A1 (en) Immunogenic compositions and uses thereof
KR20230120646A (ko) 멀티시스트론성 rna 백신 및 이의 용도
US10967057B2 (en) Zika viral antigen constructs
US20190314493A1 (en) Human cytomegalovirus vaccine
US20220241398A1 (en) Lyssavirus antigen constructs
KR102416194B1 (ko) 재조합 이스파한 바이러스 벡터
CA3142132C (en) Vaccine compositions for the treatment of coronavirus
EP4682160A1 (en) Protein and vaccine against infections of sars-cov-2 omicron mutant strain xbb and subtype thereof
EP4551710A1 (en) Self-amplifying rna encoding an influenza virus antigen
EP4661903A1 (en) Nucleic acids and uses thereof
TW202446400A (zh) 針對流行性感冒之致免疫性組成物
WO2020123777A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
KR20240099177A (ko) SARS-CoV-2 RNA 백신 조성물 및 사용 방법
RU2857683C2 (ru) Мультицистронная самореплицирующаяся РНК для эффективной экспрессии более чем одного антигена, содержащая ее фармацевтическая композиция и способы применения
US20250332245A1 (en) Immunogenic compositions against influenza
HK40095771A (zh) 预防突变株的新型冠状病毒mRNA疫苗
AU2024270076A1 (en) Combination vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)